Compare Regeneron Pharmaceuticals Inc (REGN) vs Vanguard Information Technology Index Fund ETF (VGT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Regeneron Pharmaceuticals Inc vs Vanguard Information Technology Index Fund ETF — how do they compare? Regeneron Pharmaceuticals Inc trades at $740 (market cap $76.14B), while Vanguard Information Technology Index Fund ETF trades at $128.2 (market cap $170.20B). The key difference: Vanguard Information Technology Index Fund ETF is far larger — about 2.2× Regeneron Pharmaceuticals Inc's market cap, and Regeneron Pharmaceuticals Inc pays a 0.51% dividend while Vanguard Information Technology Index Fund ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Regeneron Pharmaceuticals Inc for 107 Days and Vanguard Information Technology Index Fund ETF for 129 Days on average.
| REGN | VGT | |
|---|---|---|
Market Cap | $76.14B | $170.20B |
Volume | 500,239 | 5,132,883 |
Sector | Health | — |
52-Week High | $852.03 | $129.79 |
52-Week Low | $557.73 | $83.59 |
Typical Hold Time | 107 Days | 129 Days |
Enterprise Value | $70.85B | — |
Dividend Yield | 0.51% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Regeneron Pharmaceuticals (REGN) trades at $742.12, up 0.46% on the day, with a bearish technical signal despite strong fundamentals. The stock shows robust profitability with a 27.86% net income margin and has beaten EPS estimates for three consecutive quarters. Recent news highlights a significant $8 billion immunology alliance expansion with Sanofi, providing substantial upfront and milestone payments.
The outlook is positive due to strong earnings momentum and strategic collaborations, but risks include competitive pressures in key drug markets and technical bearish indicators. Analyst consensus is bullish with a $849.84 price target, suggesting potential upside from current levels, though investors should monitor execution of new partnerships and pipeline developments.
VGT trades at $129.37, down 0.32% on the day, with a bullish technical signal driven by moving averages. The ETF recently reached a new 52-week high, reflecting strong momentum in the technology sector. Recent news highlights its historical performance and low expense ratio compared to peers, though RSI levels suggest potential overbought conditions.
The outlook remains positive given the tech sector's growth trajectory and institutional inflows, but risks include concentration in top holdings and sensitivity to AI sector volatility. Long-term investors may benefit from sector exposure, though near-term pullbacks are possible.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →About Vanguard Information Technology Index Fund ETF
The fund employs an indexing investment approach designed to track the performance of the MSCI US Investable Market Index/Information Technology 25/50, an index made up of stocks of large, mid-size, and small US companies within the information technology sector, as classified under the GICS. The advisor attempts to replicate the target index by seeking to invest all of its assets in the stocks that make up the index, in order to hold each stock in approximately the same proportion as its weighting in the index. It is non-diversified.
Read more on VGT →
